

## Digoxin

## Order information

REF	CONTENT	Analyzer(s) on which <b>cobas c</b> pack(s) can be used
20737836 322	ONLINE TDM Digoxin 250 tests System-ID 07 3783 6	Roche/Hitachi <b>cobas c</b> 311, <b>cobas c</b> 501/502
03375790 190	Preciset TDM I Calibrators CAL A-F (6 x 5 mL) Diluent (1 x 10 mL) Codes 691-696	
04521536 190	TDM Control Set Level I (2 x 5 mL) Level II (2 x 5 mL) Level III (2 x 5 mL) Code 310 Code 311 Code 312	

## English

## System information

For **cobas c** 311/501 analyzers:

**DIG:** ACN 81

For **cobas c** 502 analyzers:

**DIG:** ACN 8081

## Intended use

In vitro test for the quantitative determination of digoxin in serum and plasma on Roche/Hitachi **cobas c** systems.

## Summary

Digoxin is a digitalis glycoside that exerts a positive inotropic effect that subsequently increases the contractile response of the myocardial fibers in patients experiencing congestive heart failure.<sup>1</sup> Cardiac glycosides also can produce several electrophysiologic effects that produce negative chronotropic effects on the human heart.<sup>2</sup> These effects tend to slow down and regulate a rapid, irregular beat like that found in patients experiencing cardiac arrhythmias.<sup>3</sup>

## Test principle

Kinetic interaction of microparticles in solution (KIMS) as measured by changes in light transmission.

The Digoxin assay is a homogeneous immunoassay based on the principle of measuring changes in scattered light or absorbance which result when activated microparticles aggregate. The microparticles are coated with digoxin and rapidly aggregate in the presence of a digoxin antibody solution. When a sample containing digoxin is introduced, the aggregation reaction is partially inhibited, slowing the rate of the aggregation process. Antibody bound to sample drug is no longer available to promote microparticle aggregation, and subsequent particle lattice formation is inhibited. Thus, a classic inhibition curve with respect to digoxin concentration is obtained, with the maximum rate of aggregation at the lowest digoxin concentration. By monitoring the change in scattered light or absorbance, a concentration-dependent curve is obtained.

## Reagents - working solutions

- R1** Anti-digoxin monoclonal antibody (mouse) and human-sourced material in buffer with preservative
- R2** Conjugated digoxin derivative microparticles, human-sourced material, and preservative

R1 is in position B and R2 is in position C.

## Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

For USA: For prescription use only.

All human material should be considered potentially infectious. All products derived from human blood are prepared exclusively from the blood of donors tested individually and shown to be free from HBsAg and antibodies to HCV and HIV.

The testing methods applied were FDA-approved or cleared in compliance with the European Directive 98/79/EC, Annex II, List A. However, as no testing method can rule out the potential risk of infection with absolute certainty, the material should be handled with the same level

of care as a patient specimen. In the event of exposure, the directives of the responsible health authorities should be followed.<sup>4,5</sup>

## Reagent handling

Ready for use

Carefully invert reagent container several times prior to use to ensure that the reagent components are mixed.

## Storage and stability

Shelf life at 2-8 °C: See expiration date on **cobas c** pack label

On-board in use and refrigerated on the analyzer: 26 weeks

## Do not freeze.

## Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

A specimen should be collected at least 6 to 8 hours after drug administration.<sup>6</sup> By this time, serum digoxin levels are expected to be in equilibrium with tissue levels and should correlate with pharmacologic effects.

Only the specimens listed below were tested and found acceptable.

Serum: Collect serum using standard sampling tubes.

Plasma: Li-heparin plasma and K<sub>2</sub>-EDTA plasma.

Stability:<sup>7</sup> 24 hours capped at 2-8 °C  
1-2 weeks capped at -20 °C

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Specimens should not be repeatedly frozen and thawed.

Invert thawed specimens several times prior to testing.

## Materials provided

See "Reagents – working solutions" section for reagents.

## Materials required (but not provided)

See "Order information" section

General laboratory equipment

## Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

The performance of applications not validated by Roche is not warranted and must be defined by the user.

## Application for serum and plasma

Deselect Automatic Rerun for these applications in the Utility menu, Application screen, Range tab.

## cobas c 311 test definition

## Digoxin

Assay type	2-Point End		
Reaction time /Assay points	10 / 9-31		
Wavelength (sub/main)	– /660 nm		
Reaction direction	Increase		
Unit	ng/mL		
Reagent pipetting		Diluent (H <sub>2</sub> O)	
R1	84 µL	–	
R2	22 µL	20 µL	
Sample volumes	Sample	Sample dilution	
		Sample	Diluent (NaCl)
Normal	5.5 µL	–	–
Decreased	5.5 µL	–	–
Increased	5.5 µL	–	–

## cobas c 501/502 test definition

Assay type	2-Point End		
Reaction time /Assay points	10 / 13-47		
Wavelength (sub/main)	– /660 nm		
Reaction direction	Increase		
Unit	ng/mL		
Reagent pipetting		Diluent (H <sub>2</sub> O)	
R1	84 µL	–	
R2	22 µL	20 µL	
Sample volumes	Sample	Sample dilution	
		Sample	Diluent (NaCl)
Normal	5.5 µL	–	–
Decreased	5.5 µL	–	–
Increased	5.5 µL	–	–

## Calibration

Calibrators	S1-6: Preciset TDM I calibrators
Calibration mode	RCM
Calibration frequency	6-point calibration <ul style="list-style-type: none"> <li>• after lot change</li> <li>• as required following quality control procedures</li> </ul>

Traceability: This method has been standardized against USP reference standards. The calibrators are prepared to contain known quantities of digoxin in normal human serum.

## Quality control

For quality control, use control materials as listed in the "Order information" section.

In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

## Calculation

Roche/Hitachi **cobas c** systems automatically calculate the analyte concentration of each sample.

Conversion factor:<sup>8</sup> ng/mL x 1.28 = nmol/L

## Limitations - interference

Criterion: Recovery within ± 10 % of initial value at a digoxin level of approximately 2.5 ng/mL (3.2 nmol/L).

## Serum/Plasma

Icterus:<sup>9</sup> No significant interference up to an I index of 60 for conjugated and unconjugated bilirubin (approximate conjugated and unconjugated bilirubin concentration: 60 mg/dL or 1026 µmol/L).

Hemolysis:<sup>9</sup> No significant interference up to an H index of 1000 (approximate hemoglobin concentration: 1000 mg/dL or 621 µmol/L).

Lipemia (Intralipid):<sup>9</sup> No significant interference up to an L index of 850. There is poor correlation between the L index (corresponds to turbidity) and triglycerides concentration.

Rheumatoid factors: No significant interference from rheumatoid factors up to 100 IU/mL.

Total protein: No interference from total protein up to 14 g/dL.

There is the possibility that other substances and/or factors may interfere with the test and cause unreliable results.

In rare instances (< 1 %), samples contain unidentified components which cause nonspecific agglutination in this assay. These samples give falsely lowered digoxin values.<sup>10</sup> If a result is obtained which is inconsistent with the patient's clinical picture, contact Customer Technical Support. Uzara and pentoxifylline were identified to cause falsely elevated digoxin values at concentrations of the recommended daily dose. Hydrocortisone does not interfere at concentrations of the recommended daily dose, however, at higher doses, as administered in life-threatening situations, hydrocortisone may cause elevated digoxin values. Endogenous substances such as DLIF (Digoxin-like immunoreactive factors) may interfere with this assay by yielding slightly elevated results.<sup>11,12,13</sup> DLIF are observed primarily in samples from neonates, pregnant women, and acute care patients with renal or hepatic failure. The manufacturer of Digoxin Immune Fab (Antibody fragment therapy) has stated that no immunoassay technique is suitable for quantitating digoxin in serum from patients undergoing this treatment.<sup>14</sup> Falsely elevated digoxin values might be obtained in patients undergoing digitoxin therapy.

As with many mouse monoclonal antibody-based immunoassays, this assay may experience interference with samples containing human anti-mouse antibodies (HAMA). Samples suspected of containing HAMA (e.g., from patients with history of mouse monoclonal antibody exposure) should be tested by an alternate method.

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.<sup>15</sup>

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

## ACTION REQUIRED

**Special Wash Programming:** The use of special wash steps is mandatory when certain test combinations are run together on Roche/Hitachi **cobas c** systems. The latest version of the carry-over evasion list can be found with the NaOHD-SMS-SmpCln1+2-SCCS Method Sheets. For further instructions refer to the operator's manual. **cobas c 502** analyzer: All special wash programming necessary for avoiding carry-over is available via the **cobas** link, manual input is not required.

**Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.**

## Limits and ranges

## Measuring range

0.3-5.0 ng/mL (0.38-6.4 nmol/L) (defined by the Limit of Detection and the upper Limit of Linearity).

Manually dilute samples above the measuring range 1 + 1 with the Preciset TDM I Diluent (0 ng/mL) and reassay. Multiply the result by 2 to obtain the specimen value.

## Limit of Blank, Limit of Detection and Limit of Quantitation/functional sensitivity

Limit of Blank = 0.2 ng/mL (0.26 nmol/L)

Limit of Detection = 0.3 ng/mL (0.38 nmol/L)

Limit of Quantitation = 0.4 ng/mL (0.51 nmol/L)

The Limit of Blank and Limit of Detection were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A requirements.

The Limit of Quantitation was determined using the result of functional sensitivity testing.

The Limit of Blank is the 95<sup>th</sup> percentile value from  $n \geq 60$  measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples.

The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

The Limit of Quantitation is the lowest Digoxin concentration that can be reproducibly measured with a between-run coefficient of variation of  $\leq 20$  %. It has been determined using low concentration digoxin samples.

#### Expected values

Accurate determination of a patient's sample digoxin concentration is necessary because of the extremely narrow therapeutic range of this drug. In addition, the significant variability of patient response even under similar dosing regimens often produces unpredictable responses in serum digoxin concentrations.<sup>16</sup> Ratios of heart/serum digoxin levels may vary between 17:1 and 35:1.<sup>17</sup>

A relationship between serum levels of digoxin and therapeutic or toxic effects has been demonstrated in numerous studies.<sup>18,19,20</sup> Therapeutic effects are seen with concentrations between approximately 0.8 and 2 ng/mL (1.0 and 2.6 nmol/L). Serum digoxin concentrations above 2 ng/mL (2.6 nmol/L) are associated with symptoms of toxicity, while concentrations less than 0.8 ng/mL (1.0 nmol/L) are generally not effective.<sup>21</sup>

Based on actual new *ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008* a therapeutic concentration range for digoxin of 0.6-1.2 ng/mL (0.77-1.5 nmol/L) is recommended.<sup>22</sup> Increased risk of mortality was observed for digoxin concentration of 1.2 ng/mL (1.5 nmol/L) and higher.<sup>23</sup>

The evaluation of test results should consider additional factors including age, renal function, and clinical symptoms of the patient.<sup>18,19,20</sup>

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

#### Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

#### Precision

Precision was determined using human samples and controls in a modified NCCLS EP5-T2 protocol (repeatability  $n = 63$ , intermediate precision  $n = 63$ ). The following results were obtained on a Roche/Hitachi cobas c 501 analyzer.

#### Serum/Plasma

Repeatability	Mean		SD		CV
	ng/mL	nmol/L	ng/mL	nmol/L	%
Control 1	0.87	1.11	0.04	0.05	4.0
Control 2	1.77	2.27	0.03	0.04	1.6
Control 3	3.03	3.88	0.03	0.04	1.0
HS 1	1.15	1.47	0.02	0.03	1.9
HS 2	2.17	2.78	0.03	0.04	1.5
Intermediate precision	Mean		SD		CV
	ng/mL	nmol/L	ng/mL	nmol/L	%
Control 1	0.87	1.11	0.05	0.06	6.0
Control 2	1.77	2.27	0.04	0.05	2.4
Control 3	3.03	3.88	0.05	0.06	1.6
HS 1	1.15	1.47	0.04	0.05	3.2
HS 2	2.17	2.78	0.05	0.06	2.2

#### Method comparison

#### Serum/plasma

Digoxin values for human serum and plasma samples obtained on a Roche/Hitachi cobas c 501 analyzer (y) were compared with those determined using the corresponding reagent on a COBAS INTEGRA 800 analyzer (x).

COBAS INTEGRA 800 analyzer	Sample size (n) = 87
Passing/Bablok <sup>24</sup>	Linear regression
$y = 0.980x + 0.039$ ng/mL	$y = 0.969x + 0.047$ ng/mL
$r = 0.931$	$r = 0.995$

The sample concentrations were between 0.331 and 4.38 ng/mL (0.424 and 5.61 nmol/L).

#### Analytical specificity

The following compounds were tested for cross-reactivity.

Compound	Concentration Tested (ng/mL)	% Cross-reactivity
β-Acetyldigoxin	2.0	82.5
Digitoxin	48.8	4.5
Digitoxigenin	39	1.2
Digoxigenin	25	8.6
Digoxigenin bis-digitoxose	2	130
Digoxigenin mono-digitoxose	2	107.5
Dihydrodigoxin	20	6.5
β-Methyl digoxin	1	115
Dehydroisoandrosterone	10000	ND
Digitoxose	10000	ND
Estradiol	10000	ND
Estriol	10000	ND
Hydrocortisone	10000	ND
11-Hydroxyprogesterone	10000	ND
17-Hydroxyprogesterone	10000	ND
Prednisolone	10000	ND
Prednisone	10000	ND
Progesterone	10000	ND
Spironolactone	10000	0.01

ND = Not Detected

Tests were performed on 16 drugs. No significant interference with the assay was found.

Acetaminophen	Doxycycline (Tetracycline)
Acetyl cysteine	Ibuprofen
Acetylsalicylic acid	Levodopa
Ampicillin-Na	Methyldopa + 1.5 H <sub>2</sub> O
Ascorbic acid	Metronidazole
Ca-Dobesilate	Phenylbutazone
Cefoxitin	Rifampicin
Cyclosporine	Theophylline

#### References

- 1 Lee KS, Klaus W. The subcellular basis for the mechanism of inotropic action of cardiac glycosides *Pharmacol Rev* 1971;23:193-261.
- 2 Hoffman BF. In: Fisch C, Surawicz B, eds. Effects of digitalis on electrical activity of cardiac fibers. *Digitalis*. New York, NY: Grune and Stratton 1969;93-109.

- 3 Moe GK, Farah AE. In: Goodman LS, Gilman A, eds. Digitalis and allied cardiac glycosides. The Pharmacologist Basis of Therapeutics. New York, NY: MacMillan Company 1970.
- 4 Occupational Safety and Health Standards: bloodborne pathogens. (29 CFR Part 1910.1030). Fed. Register.
- 5 Directive 2000/54/EC of the European Parliament and Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work.
- 6 Jortani SA, Valdes R Jr. Digoxin and its related factors. Crit Rev Clin Lab Sci 1997;34(3):225-274.
- 7 Valdes R Jr, Jortani S, Gheorghiade M. Standards of laboratory practice: cardiac drug monitoring. Clin Chem 1998;44(5):1096-1109.
- 8 Tietz NW, ed. Clinical Guide to Laboratory Tests, 3rd ed. Philadelphia, PA: WB Saunders Company 1995;46.
- 9 Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
- 10 Data on file at Roche Diagnostics.
- 11 Keys PW, Stafford RW. In: Taylor WJ, Finn AL, eds. Individualizing Drug Therapy: Practical Applications of Drug Monitoring. New York, NY: Gross Townsend Frank Inc 1981;vol 3:1-21.
- 12 Valdes R Jr. Endogenous digoxin-like immunoreactive factors: Impact on digoxin measurements and potential physiological implications. Clin Chem 1985;31:1525-1532.
- 13 Scholer A, Boecker J, Engelmayer U et al. Comparability of a new turbidimetric digoxin test with other immunochemical tests and with HPLC - a multicenter evaluation. Clin Chem 1997;43:92-99.
- 14 Digibind Product Information. Burroughs Wellcome Co. Research Triangle Park, NC 1990.
- 15 Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. Clin Chem Lab Med 2007;45(9):1240-1243.
- 16 Lindenbaum J, Mellow MH, Blackstone MO, et al. Variation in the biologic availability of digoxin from four preparations. New Engl J Med 1971;285:1344-1347.
- 17 Doherty JE, Perkins WH, Flanigan WJ. The distribution and concentration of titrated digoxin in human tissues. Ann Intern Med 1967;66:116.
- 18 Smith TW, Haber E. Digoxin intoxication: the relationship of clinical presentation to serum digoxin concentration. J Clin Invest 1970;49:2377-2386.
- 19 Reuning RH, Sams RA, Notari RE. Role of pharmacokinetics in drug dosage adjustment. I. Pharmacokinetic effect and apparent volume of distribution of digoxin. J Clin Pharmacol 1973;13:127-141.
- 20 Whiting B, Sumner DJ, Goldberg A. An assessment of digoxin radioimmunoassay. Scott Med J 1973;18:69-74.
- 21 Huffman DH, Crow JW, Pentikainen P, et al. Clinical cardiac status, laboratory parameters and digoxin usage. Am Heart J 1976;91:28.
- 22 Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442.
- 23 Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289(7):871-878.
- 24 Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

**Symbols**

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard.

CONTENT
---------

Contents of kit



Volume after reconstitution or mixing

GTIN
------

Global Trade Item Number

**FOR US CUSTOMERS ONLY: LIMITED WARRANTY**

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship until the expiration date printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.

COBAS, ONLINE TDM, COBAS C, PRECISET and COBAS INTEGRA are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2015, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim  
www.roche.com

Distribution in USA by:  
Roche Diagnostics, Indianapolis, IN  
US Customer Technical Support 1-800-428-2336

